AUBURNDALE, MA--(Marketwired - April 06, 2016) - UltraSPECT Inc., a leading provider of image reconstruction solutions supporting safer and faster nuclear cardiology and oncology exams, today announced the 10th anniversary of the FDA approval of its Wide Beam Reconstruction (WBR™) Technology, an iterative reconstruction imaging algorithm to enable lower dose and shorter time imaging for nuclear medicine exams. An early entrant to the market, UltraSPECT has had double-digit growth in both annual revenue and annual units sold for the last few years. Factors like the recently introduced American Society of Nuclear Cardiology (ASNC) low-dose guidelines, heightened patient awareness to the risks of exposure to radiation, and new CMS reimbursement penalties have accelerated the quest by hospitals to implement emerging low dose and ultra-low dose nuclear medicine technologies and fueled UltraSPECT sales.

"Ten years ago, UltraSPECT had the vision of 'WBR inside' to replace other reconstructed technologies like FBP/ OSEM algorithms with WBR iterative reconstruction imaging algorithm at all nuclear medicine facilities in the U.S.," said Yossi Srour, President and CEO, UltraSPECT. "Today, we are thrilled to have the market ready, and to see more and more hospitals proactively embracing the benefits of low-dose nuclear medicine imaging to support safer and faster imaging for their patients and their staff."

In 2006, UltraSPECT introduced to the U.S. market the first application for shorter time patient imaging both for oncology and cardiology exams, and followed that with the enhanced technology for both shorter time and lower dose imaging in 2008. The resulting benefit is enhanced value to physicians, technologists, patients, administrators and radiopharmaceutical suppliers of reduced dose, shorter scans and increased patient comfort with images as good, if not better in diagnostic quality, than those provided with traditional SPECT acquisition. With these benefits, and solutions that are also the most cost-effective for dose reduction, UltraSPECT has achieved the following key milestones:
Double-digit revenue growth for the past three years
More than 200 units sold between 2013-2015
Installations in 46 states
16 distribution partners, including 8 different radiopharmaceutical pharmacies
Compatibility with 41 different gamma cameras and 12 workstations representing all the major manufacturers
100% field validation

Market Analysis Homepage